News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,909 Results
Type
Article (40018)
Company Profile (250)
Press Release (664640)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204280)
Career Advice (2011)
Deals (35455)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345507)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1444)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2870)
Cardiovascular disease (213)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66858)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2624)
CRISPR (56)
C-suite (329)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (126)
Earnings (87456)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113745)
Executive appointments (845)
FDA (17902)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (374)
GLP-1 (783)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19585)
Metabolic disorders (849)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2121)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57690)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29449)
Phase III (21919)
Pipeline (1637)
Policy (200)
Postmarket research (2563)
Preclinical (8871)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (89)
Last 7 days (347)
Last 30 days (1819)
Last 365 days (31198)
2025 (16804)
2024 (35220)
2023 (40077)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38212)
Australia (6232)
California (7441)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82110)
Florida (1118)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (637)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5529)
Michigan (246)
Minnesota (450)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2080)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3277)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2784)
Tennessee (126)
Texas (1126)
United States (27576)
Utah (220)
Virginia (185)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,909 Results for "systimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025
May 9, 2025
·
4 min read
Press Releases
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress 2025
May 23, 2025
·
5 min read
Business
SystImmune, Inc. Announces Transition of Chief Medical Officer
SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates for the treatment of cancer, announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer.
May 23, 2024
·
2 min read
Business
SystImmune, Inc. Appoints Dr. Jie D’Elia as Chief Executive Officer
SystImmune, Inc. today announced the appointment of Jie D’Elia, Ph.D., MBA, as its new Chief Executive Officer.
April 22, 2024
·
2 min read
Press Releases
SystImmune, Inc. Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
November 26, 2024
·
4 min read
Press Releases
SystImmune, Inc. to Present Updated BL-B01D1 Data in Breast Cancer at SABCS Congress 2024
December 11, 2024
·
4 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors
November 8, 2024
·
3 min read
BioForest
SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of pivotal data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2023.
October 20, 2023
·
5 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
October 14, 2024
·
3 min read
Business
BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer
Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.
December 12, 2023
·
2 min read
·
Tristan Manalac
1 of 70,491
Next
